Patents
Literature
Hiro is an intelligent assistant for R&D personnel, combined with Patent DNA, to facilitate innovative research.
Hiro

125results about "Calcium binding proteins" patented technology

Bone/joint disease sensitivity gene and use thereof

The present invention provides the prophylaxis and treatment of bone and joint diseases by regulating the expression or activity of calmodulin, the prophylaxis and treatment of bone and joint diseases by regulating the expression or activity of asporin, and a diagnostic method for genetic susceptibility to bone and joint diseases by detecting polymorphisms in the CALM1 gene and / or the asporin gene, and the like.
Owner:TAKEDA PHARMA CO LTD +1

Generation of Plants with Altered Oil Content

The present invention is directed to plants that display an altered oil content phenotype due to altered expression of a HIO128.5 nucleic acid. The invention is further directed to methods of generating plants with an altered oil content phenotype.
Owner:EXELIXIS PLANT SCI INC

Activatable cell penetrating peptides with quenched fluorophores

The invention provides compositions useful as molecular probes. In particular, the invention provides activatable cell penetrating peptides comprising a fluorescence donor and a fluorescence acceptor. Exemplary fluorescence donors and fluorescence acceptors include compounds derived from cyanine. Also provided are ratiometric, multispectral, and excitation lifetime imaging methods for detecting the molecular probes provided herein.
Owner:RGT UNIV OF CALIFORNIA

Purification and characterization of soluble mhc proteins

InactiveUS20100105107A1Improve purification effectFacilitates increased expressionAntibody mimetics/scaffoldsVirus peptidesADAMTS ProteinsSoluble hla
The present invention relates generally to the production and use of functionally active soluble HLA molecules that are isolated and purified substantially away from other proteins, and methods of purifying same.
Owner:HILDEBRAND WILLIAM H +1

Activatable cell penetrating peptides with quenched fluorophores

The invention provides compositions useful as molecular probes. In particular, the invention provides activatable cell penetrating peptides comprising a fluorescence donor and a fluorescence acceptor. Exemplary fluorescence donors and fluorescence acceptors include compounds derived from cyanine. Also provided are ratiometric, multispectral, and excitation lifetime imaging methods for detecting the molecular probes provided herein.
Owner:RGT UNIV OF CALIFORNIA

Human S100 proteins

The invention provides two human S100 proteins designated individually as S100P1 and S10OP2 and collectively as S100P, and polynucleotides which identify and encode S100P. The invention also provides expression vectors, host cells, agonists, antibodies and antagonists. The invention also provides methods for treating disorders associated with expression of S100P.
Owner:INCYTE PHARMA INC

Neural specific s100b for biomarker assays and devices for detection of a neurological condition

An in vitro diagnostic (IVD) device is used to detect the presence of and / or severity of neural injuries or neuronal disorders in a subject. The IVD device relies on an immunoassay which identifies biomarkers that are diagnostic of neural injury and / or neuronal disorders in a biological sample, such as whole blood, plasma, serum, and / or cerebrospinal fluid (CSF). An IVD device may measure one or more of several neural specific markers in a biological sample and output the results to a machine readable format, either to a display device or to a storage device internal or external to the IVD.
Owner:BANYAN BIOMARKERS INC

Mutant calreticulin for the diagnosis of myeloid malignancies

The present invention relates to a method for diagnosing myeloid malignancy comprising determining the presence of a mutant allele of the calreticulin gene. Also genomic sequences, cDNA sequences, mRNA sequences and protein sequences of the mutant calreticulin are subject of the present invention. Further, the invention relates to medical uses of inhibitors of mutant calreticulin.
Owner:CEMM FORSCHUNGSZENT FUR MOLEKULARE MEDIZIN

Immunomodulatory agents for treatment of inflammatory diseases

The present invention provides methods and compositions suitable for treating inflammatory disorders such as allergy, asthma, artherosclerosis, autoimmune disease, infection, injury, meningitis, psoriasis, and transplant rejection. In particular, the present invention provides methods and compositions comprising human S100A8 and / or S100A9 for reducing inflammation.
Owner:RGT UNIV OF CALIFORNIA

Set of Polypeptides Exhibiting Nuclease Activity or Nickase Activity with Dependence on Light or in Presence of Drug or Suppressing or Activating Expression of Target Gene

The present invention provides, for example, a set of two polypeptides exhibiting the nuclease activity with dependence on light or in the presence of a drug, in which an N-terminal side fragment and a C-terminal side fragment of a Cas9 protein are bound to each of two polypeptides which form a dimer with dependence on light or in the presence of a drug.
Owner:THE UNIV OF TOKYO

Cc2d2a gene mutations associated with joubert syndrome and diagnostic methods for identifying the same

The present invention provides a method of screening a subject for mutations in the CC2D2A gene that are associated with Joubert syndrome, an autosomal recessive form of mental retardation. The present invention also provides proteins that are associated with Joubert syndrome including proteins comprising an amino acid sequence that terminates in DHEGGSGMES (SEQ ID NO: 1). Also provided are nucleotide sequences encoding such proteins and methods of screening subjects to identify nucleotide sequences or proteins associated with Joubert syndrome.
Owner:CENT FOR ADDICTION & MENTAL HEALTH

Single-molecule-format real-time bioluminescence imaging probe

InactiveUS20090176239A1Convenient bioluminescence analysis methodBroad spectrumAnimal cellsSugar derivativesExtinctionIn vivo
The present invention provides an “in vivo and in vitro real-time bioluminescence imaging means,” which can transmit a detection signal promptly in response to an external signal, while taking advantage of a single-molecule-format luminescent probe as a bioluminescent means.The present invention is characterized by using, as a single-molecule-format luminescent probe utilizing the increase and decrease of a second messenger level as an index, a fusion protein including a single-chain protein containing a second messenger recognition protein and optionally a peptide which is capable of binding with the protein, and linked respectively to the N-terminus and the C-terminus thereto, an N-terminal fragment (N-LE) and a C-terminal fragment (C-LE) generated by dissecting a luminescent enzyme (LE). A single-molecule-format luminescent probe could be provided, which makes it possible to observe light emission (extinction) in vivo as well as in vitro, as a result of a conformational change of the second messenger recognition protein induced by the binding (unbinding) with a second messenger, and the subsequent association or dissociation between the N-LE and the C-LE flanked at both termini of the recognition protein.
Owner:NAT INST OF ADVANCED IND SCI & TECH

Fluorescent protein-based calcium integrators

The presently-disclosed subject matter includes fluorescent protein-based indicators for detecting ions, small molecule analytes, or combinations thereof. In some embodiments the indicators include a polypeptide, which itself includes a fluorescent polypeptide, a compound-binding polypeptide, and a polypeptide target of the compound-binding polypeptide. In some embodiments the polypeptide includes an EosFP polypeptide, a calmodulin polypeptide, and a M13 polypeptide, or fragments and / or variants thereof. The presently-disclosed subject matter also includes methods for detecting calcium in a sample with embodiments of the present polypeptides. In some embodiments the present indicators experience a permanent shift from green to red fluorescent when exposed to an detecting substance, such as calcium.
Owner:HOWARD HUGHES MEDICAL INST

Polypeptide capable of regulating glycometabolism and application thereof

The invention relates to a polypeptide capable of regulating glycometabolism and application thereof to preparation of medicines for treating diseases related to the glycometabolism. The polypeptide can lower blood sugar and promote insulin secretion, can be applied to preparation of medicines for treating diabetes, and can be combined with the existing therapeutic schemes for use. The polypeptide has the significant advantages as follows: the polypeptide is low in therapeutic effective dose, can be orally administered and the like.
Owner:深圳中科新进生物科技有限公司

Purification and characterization of soluble human HLA proteins

InactiveUS20060276629A9Improve purification effectFacilitates increased expressionAntibody mimetics/scaffoldsVirus peptidesSoluble hlaMolecular biology
The present invention relates generally to the production and use of functionally active soluble HLA molecules that are isolated and purified substantially away from other proteins, and methods of purifying same.
Owner:THE BOARD OF RGT UNIV OF OKLAHOMA

Micromolecular protein used for indicating calcium ions and application of micromolecular protein

The invention provides micromolecular protein used for indicating calcium ions and an application of the micromolecular protein. The amino acid sequence of the micromolecular protein is shown in SEQ ID NO.1. The gene encoded micromolecular protein is named as GEM and is blended with CaM (calmodulin) and myosin light-chain kinase M13, and numerous defects in existing calcium imaging technologies can be overcome. A new calcium imaging technology which takes the whole situation and the microscopic situation into consideration and can record activity in brains of experiment animals freely moving in the true sense can be obtained with the adoption of the micromolecular protein, and the micromolecular protein has broad application prospects and huge market value.
Owner:SHENZHEN INST OF ADVANCED TECH

Fluorescent protein-based indicators

The presently-disclosed subject matter includes fluorescent protein-based indicators for detecting ions, small molecule analytes, or combinations thereof. In some embodiments the indicators include a polypeptide, which itself includes a fluorescent polypeptide, a compound-binding polypeptide, and a polypeptide target of the compound-binding polypeptide. In some embodiments the polypeptide includes an EosFP polypeptide, a calmodulin polypeptide, and a M13 polypeptide, or fragments and / or variants thereof. The presently-disclosed subject matter also includes methods for detecting calcium in a sample with embodiments of the present polypeptides. In some embodiments the present indicators experience a permanent shift from green to red fluorescent when exposed to an detecting substance, such as calcium.
Owner:HOWARD HUGHES MEDICAL INST

Recombinant clostridial neurotoxins with enhanced membrane localization

This invention relates to novel recombinant clostridial neurotoxins exhibiting increased membrane localization and to methods for the manufacture of such recombinant clostridial neurotoxins. These methods comprise the steps of inserting a nucleic acid sequence coding for a C2 domain into a nucleic acid sequence coding for a parental clostridial neurotoxin and expression of the recombinant nucleic acid sequence comprising the C2 domain in a host cell. The invention further relates to novel recombinant single-chain precursor clostridial neurotoxins used in such methods, nucleic acid sequences encoding such recombinant single-chain precursor clostridial neurotoxins, and pharmaceutical compositions comprising the recombinant clostridial neurotoxin with increased membrane localization.
Owner:MERZ PHARMA GMBH & CO KGAA

Methods for removing anti-MHC antibodies from a sample

The present invention relates generally to anti-MHC assay methodologies utilizing functionally active, recombinantly produced, and truncated individual soluble MHC trimolecular complexes that are linked to a substrate. The methods include reacting a sample with the substrate having the MHC trimolecular complex linked thereto, whereby antibodies specific for the at least one MHC trimolecular complex linked to the substrate are removed from the biological sample.
Owner:HILDEBRAND WILLIAM H +1

Design and application of gene coding calcium probe GCaMP-X

ActiveCN107987171AReduce the impactChanges in the real objective concentrationCompound screeningApoptosis detectionNitrogenExcitation transcription coupling
The invention discloses an optimized and improved gene coding calcium probe GCaMP-X and basic application thereof. The probe comprises a GCaMP protein, a first amino acid sequence and a second amino acid sequence, wherein the first amino acid sequence refers to fragments capable of weakening pre-binding capacity between calmodulin un-bound with calcium ions and an L type calcium channel (LTCC); the second amino acid sequence is a localization sequence (intranuclear, extranuclear and other subcellular regions); the first amino acid sequence is located at a nitrogen terminal of the GCaMP protein; and the second amino acid sequence is located at a carbon terminal of the GCaMP protein. Compared with each kind of the conventional GCaMP probes, the optimized GCaMP-X probe has effects of eliminating interference effects on nerve cell LTCC and mediated excitation-transcription coupling thereof and objectively and accurately measuring calcium signals of nerve cells.
Owner:TSINGHUA UNIV

Polypeptide capable of regulating energy metabolism and application of polypeptide

ActiveCN107011427AFew residuesReduce the inconvenience of applicationPeptide/protein ingredientsMetabolism disorderDiseaseBULK ACTIVE INGREDIENT
The invention relates to a polypeptide capable of regulating energy metabolism and application of the polypeptide in preparation of medicines for treating diseases related to disorder of energy metabolism (particularly fat metabolism). The polypeptide disclosed by the invention can achieve the effects of reducing fat absorption, lowering fat accumulation in the liver and regulating the fat metabolism; and compared with a general polypeptide product, the polypeptide disclosed by the invention has the advantage of being orally applied. Therefore, the polypeptide can serve as an active ingredient of a health care product used for regulating the fat metabolism.
Owner:深圳中科新进生物科技有限公司

Compositions and methods for expression of multiple biologically active polypeptides from a single vector for treatment of cardiac conditions and other pathologies

ActiveUS20180360992A1Promote neovascularizationLocal broadeningPeptide/protein ingredientsAntibody mimetics/scaffoldsHeart diseaseCytokine
The present invention provides compositions and methods useful for treating disorders amenable to therapy via introduction of multigenic expression vectors. More particularly, the invention provides vectors and polynucleotides encoding polypeptides for treatment of cardiac disorders wherein said polypeptides may comprise a cytokine, a chemokine, and / or an angiogenic polypeptide, or functional derivatives thereof. Also provided, as compositions of the invention, are linkers useful for connecting and expressing functional (biologically active) polypeptides from single, multigenic-expression constructs.
Owner:PRECIGEN INC

Promoter pCALM2 and application thereof

The invention discloses a promoter pCALM2 and an application thereof. The nucleotide sequence of the promoter pCALM2 is as shown in SEQ ID NO: 1. The promoter pCALM2 can be applied to recombinant adeno-associated viruses, so that exogenous genes can be efficiently expressed in the forebrain, and the promoter pCALM2 has a wide application prospect in the fields of neural circuit tracing and gene therapy.
Owner:SHENZHEN INST OF ADVANCED TECH CHINESE ACAD OF SCI

Method of purifying calcium ion-binding protein

The present invention relates to a method for purifying a calcium ion-binding protein by cation exchange chromatography. The present invention provide a method for isolating and purifying a calcium ion-binding protein in a simple and efficient manner from a liquid sample containing a calcium ion-binding protein and contaminants without any pretreatment such as addition of a chelating agent. More specifically, the present invention relates to a method for purifying a calcium ion-binding protein which comprises contacting said protein with a cation exchange carrier in the presence of calcium ions to let the said protein be adsorbed to the carrier, and after washing, eluting said protein, and to a calcium ion-binding protein having substantially no contaminants obtained by the method of the present invention.
Owner:JURIDICAL FOUND THE CHEMO SERO THERAPEUTIC RES INST +1

S100B mutant and application thereof

The invention belongs to the technical field of protein engineering and particularly relates to a S100B mutant and application thereof. The DNA sequence of the S100B mutant is SEQ ID No:6. A S100B mutant protein has good affinity with an antibody when used as an antigen, and a prepared antibody has high purity. Simultaneously, the S100B mutant protein is easier to elute compared with a non-mutantS100B protein, and the antibody recovery rate is greatly improved.
Owner:青岛瑞斯凯尔生物科技有限公司
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Patsnap Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Patsnap Eureka Blog
Learn More
PatSnap group products